Celestial Biolabs launches patented arthritis mgmt product

Bio-pharmaceutical company Celestial Biolabs Ltd today said it has launched a new product 'Cadalmin GAe', which is a break through research in the management of arthritis and all joint pains.
BSE & NSE listed, Celestial Biolabs is manufacturing and marketing the product from patented technology from a natural marine bio-active anti-inflammatory ingredient extracted from macro algae.
'Cadalmin GAe' provides relief to people suffering from arthritis, rheumatoid arthritis and is recommended for patient having uric acid problems, a company statement said.
This product is developed at CMFRI (Central Marine Fisheries Research Institute), an institute of Indian Council of Agricultural Research.
Results of experimental & clinical study exhibited Cadalmin GAe to be mother nature's first ever effective, well tolerated, safe research molecule without any side effects. Some of the other leading products of Celestial Bio Labs are Biovita; Bioliv; O-kof; Cel Clear; Gynocel; Rhumacel; Cel Digest and Relifin.

Celestial Bio labs is engaged in bio pharmaceuticals formulations, consisting of herbal products, nutraceuticals, enzyme formulations.